Clarithromycin Stella Contraindications

Hypersensitivity to macrolide antibiotic drugs or to any of its excipients.
Concomitant administration of clarithromycin and ergot alkaloids (e.g. ergotamine or dihydroergotamine) is contraindicated, as this may result in ergot toxicity.
Concomitant administration of clarithromycin and oral midazolam is contraindicated.
Concomitant administration of clarithromycin and any of the following drugs is contraindicated: astemizole, cisapride, pimozide and terfenadine as this may result in QT prolongation and cardiac arrhythmias, including ventricular tachycardia, ventricular fibrillation, and torsades de pointes.
Clarithromycin should not be given to patients with history of QT prolongation (congenital or documented acquired QT prolongation) or ventricular cardiac arrhythmia, including torsades de pointes.
Concomitant administration with ticagrelor or ranolazine is contraindicated.
Clarithromycin should not be used concomitantly with HMG-CoA reductase inhibitors (statins) that are extensively metabolized by CYP3A4 (lovastatin or simvastatin) due to the increased risk of myopathy, including rhabdomyolysis.
As with other strong CYP3A4 inhibitors, clarithromycin should not be used in patients taking colchicine.
Clarithromycin should not be given to patients with hypokalaemia (risk of prolongation of QT time).
Clarithromycin should not be used in patients who suffer from severe hepatic failure in combination with renal impairment.